Cover Image
市場調查報告書

癌症的生物學的治療:技術及全球市場

Biological Therapies for Cancer: Technologies and Global Markets

出版商 BCC Research 商品編碼 117617
出版日期 內容資訊 英文 346 Pages
訂單完成後即時交付
價格
Back to Top
癌症的生物學的治療:技術及全球市場 Biological Therapies for Cancer: Technologies and Global Markets
出版日期: 2015年01月09日 內容資訊: 英文 346 Pages
簡介

全球癌症的生物學的療法市場預計2014年從約512億美金,2014年到2019年以5.4%的年複合成長率推移,2019年達到664億美元。

本報告提供全球癌症的生物學的療法市場及技術的相關調查,世界市場趨勢分析、上市藥、市場結構與競爭環境、癌症市場、生技仿製藥對市場的影響等相關詳細的分析、更有效的癌症治療藥的研究開發(R&D)及正在開發、臨床實驗階段的新治療藥主要的課題,及主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 癌症的生物學的治療

  • 癌症定義
  • 癌症增生的原因
  • 癌症治療策略

第4章 癌症的說明

  • 肺癌
  • 膀胱癌
  • 乳癌
  • 子宮頸癌
  • 直腸癌
  • 小腸癌
  • 食道癌
  • 腎臟癌
  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤
  • 腦瘤
  • 卵巢癌
  • 胰臟癌
  • 前列腺癌
  • 胃癌
  • 頭頸癌

第5章 產品區分、技術

  • 單株抗體
  • 干擾素(interferon)
  • 疫苗
  • 顆粒細胞增生因子(G-CSF)
  • 生技仿製藥
  • 其他生物學的療法及遺傳基因療法

第6章 市場動態、概要

  • 開發平台生技藥品
  • 全球癌症市場趨勢
  • 全球腫瘤學市場
  • 全球癌症生物學療法市場
  • 新的開發
  • 癌症疫苗

第7章 開發中的產品

  • 最新的開發、認證
  • 正在開發的新藥和企業
  • 臨床實驗
  • 腫瘤學的臨床實驗
  • 結論

第8章 腫瘤治療藥市場

  • 市場規模、成長率
  • 腫瘤學市場、成長率
  • BIOMAB-EGFR
  • 市場資料:按暢銷生物製藥

第9章 全球癌症統計

  • 全球癌症發病率
  • 癌症趨勢
  • 目前癌症趨勢、經濟負擔

第10章 癌症的生物學的治療市場上課題與趨勢

  • Medicare和醫療政策
  • 癌症的成本
  • 全球趨勢
  • 生技仿製藥
  • 創業投資與研究投資
  • 結論

第11章 企業簡介

  • 生物學的企業
  • 主要企業簡介

第12章 參照

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BIO048C

The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.

This report provides:

  • An overview of the global markets and technologies for biological therapies for cancer
  • Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.
  • Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.
  • A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
  • Comprehensive profiles of major players in the cancer biotherapeutics field.

image1

REPORT SCOPE

SCOPE AND FORMAT

This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.

The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons. The biologic drug classes discussed in this report with special focus on cancer treatment are:

  • Monoclonal antibodies.
  • Vaccines.
  • Erythropoietin.
  • Colony stimulating factors.
  • Interleukins and interferons.

The following approaches to cancer therapeutics are excluded in the report:

  • Chemotherapy.
  • Alkylating agents.
  • Antimetabolites.
  • Cytotoxic agents.
  • Plant derivatives and hormone therapy corticosteroids.
  • Hormone antagonists/antagonists aromatase inhibitors.
  • Radiation therapy.
  • Adjunctive therapy.

Biological therapies for treatment of other diseases will not be addressed in this report. The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:

  • Treatment trends and sales patterns across major cancer indications for Japan, Europe E.U.5 nations (i.e., France, Germany, Italy, Spain, the U.K.), the U.S. and the rest of the world (ROW).
  • Market performance of major pharmaceutical companies.
  • Forecast sales of leading products across major indications to 2019.
  • Biosimilars and their impact on currently marketed cancer biotherapeutics.

ANALYST'S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of pre-clinical, alliance management, discovery and technology development, and marketing experience. Her primary focus areas include oncology and cardiovascular diseases, along with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She also has experience working with early start-up companies.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE AND FORMAT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • RELATED BCC RESEARCH REPORTS
  • ANALYST'S CREDENTIALS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019 ($ MILLIONS)

CHAPTER 3 BIOLOGICAL TREATMENTS FOR CANCER

  • DEFINING CANCER
  • CAUSES OF CANCER GROWTH
  • CANCER TREATMENT STRATEGIES
    • COMMON TREATMENTS AND PROBLEMS
      • Surgery
      • Chemotherapy
      • Radiation Treatment
      • Targeted Therapy
      • Hormone Therapy
    • BIOLOGICAL THERAPY OF CANCER

CHAPTER 4 CANCER DESCRIPTIONS

  • TABLE 1 MAIN CANCER CATEGORIES
  • LUNG CANCER
    • LUNG CANCER TREATMENT
    • BIOLOGIC USE
  • BLADDER CANCER
  • BREAST CANCER
    • HER2 EXPRESSION
      • Antiangiogenic and HER2 Agents
  • CERVICAL CANCER
    • VACCINES
    • DIAGNOSIS
    • TREATMENT
    • Avastin
  • COLORECTAL CANCER
  • SMALL INTESTINE CANCER
  • ESOPHAGEAL CANCER
  • KIDNEY CANCER
    • TARGETED THERAPIES FOR KIDNEY CANCER
    • TABLE 2 APPROVED RENAL CELL CANCER DRUGS
      • Sorafenib
      • Sunitinib
      • Temsirolimus
      • Everolimus
      • Bevacizumab
      • Pazopanib
      • Axitinib
  • LEUKEMIA
    • SYMPTOMS AND TREATMENT
  • LYMPHOMA
    • NON-HODGKIN'S LYMPHOMA
    • TABLE 3 MONOCLONAL ANTIBODIES FOR NON-HODGKIN'S LYMPHOMA TREATMENT
      • Extranodal B-cell Lymphoma of Mucosa Associated Lymphoid Tissue
      • Mantle Cell Lymphoma
      • Mediastinal Diffuse Large B-Cell Lymphoma
      • Burkitt Lymphoma
  • LIVER CANCER
  • MELANOMA
    • METASTATIC MELANOMA
  • MULTIPLE MYELOMA
  • BRAIN CANCER
  • TABLE 4 BRAIN TUMOR SPECIFIC STATISTICS
    • GLIOMAS
    • TABLE 5 ASTROCYTOMAS
    • MENINGIOMAS
    • ACOUSTIC NEUROMAS AND SCHWANNOMAS
    • MEDULLOBLASTOMA
  • OVARIAN CANCER
    • DIAGNOSIS
  • PANCREATIC CANCER
  • PROSTATE CANCER
  • STOMACH CANCER
  • TABLE 6 STOMACH CANCER TYPES
  • TABLE 7 ADENOCARCINOMA STOMACH CANCER STAGES
    • CLINICAL TRIALS
  • HEAD AND NECK CANCERS
  • TABLE 8 HEAD AND NECK CANCER TYPES

CHAPTER 5 PRODUCT SEGMENTS AND TECHNOLOGY

  • TABLE 9 GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 1 GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, 2008-2019 ($ MILLIONS)
  • MONOCLONAL ANTIBODIES
  • TABLE 10 MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
    • THE FUTURE OF CANCER MONOCLONALS
    • TABLE 11 ANTIBODY-BASED DEVELOPMENTS WITH EPITHELIAL CELL-ADHESION MOLECULE
    • MONOCLONALS ON THE MARKET
      • Rituxan
      • TABLE 12 GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014 ($ MILLIONS)
      • FIGURE 2 GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014 ($ MILLIONS)
      • TABLE 13 U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009 ($ MILLIONS)
      • FIGURE 3 U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009 ($ MILLIONS)
      • Avastin
      • Herceptin
      • Campath
      • Erbitux
      • TABLE 14 ERBITUX APPROVALS
        • Approved for KRAS Wild-Type, Epidermal Growth Factor Receptor-Expressing Metastatic Colorectal Cancer
        • Approved for Recurrent or Metastatic Head and Neck Cancers
        • Head and Neck Cancers
        • Colorectal Cancer
      • Mylotarg
      • Vectibix
      • Bexxar
      • Zevalin
  • INTERFERONS
  • TABLE 15 GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014 ($ MILLIONS)
  • FIGURE 4 GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014 ($ MILLIONS)
    • ALDESLEUKIN
    • INTERFERON ALPHA
  • VACCINES
    • THERAPEUTIC AND PREVENTATIVE CANCER VACCINES
    • PREVENTIVE CANCER VACCINES
    • TABLE 16 GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014 ($ MILLIONS)
    • FIGURE 5 GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014 ($ MILLIONS)
      • Gardasil
  • GRANULOCYTE COLONY STIMULATING FACTOR
  • TABLE 17 GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014 ($ MILLIONS)
  • FIGURE 6 GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014 ($ MILLIONS)
    • ARANESP
    • PROCRIT AND EPOGEN
    • OMONTYS
    • NEULASTA
    • NEUPOGEN
    • LEUKINE/SARGRAMOSTIM
    • NEUMEGA
  • BIOSIMILARS
    • BIOCON
  • OTHER BIOTHERAPY AND GENE THERAPY

CHAPTER 6 MARKET DYNAMICS AND OVERVIEW

  • TABLE 18 GLOBAL BIOLOGICS SALES, 2013 ($ MILLIONS)
  • PIPELINE BIOLOGICS
    • STANDARD TREATMENTS
  • GLOBAL CANCER MARKET TRENDS
  • TABLE 19 GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • FIGURE 7 GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • TABLE 20 GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • FIGURE 8 GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • TABLE 21 APPROVED ONCOLOGY DRUGS, 2013-2014
  • GLOBAL ONCOLOGY MARKET
  • TABLE 22 GLOBAL ONCOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • FIGURE 9 GLOBAL ONCOLOGY MARKET BY REGION, 2008-2019 ($ MILLIONS)
    • PAST PERFORMANCE OF CANCER DRUGS
    • TABLE 23 GLOBAL ONCOLOGY SALES, 2012 AND 2013 ($ MILLIONS/%)
    • EMERGING MARKETS
    • TABLE 24 ASIA-PACIFIC SOLID TUMOR MARKET, THROUGH 2019 ($ MILLIONS)
    • TABLE 25 ASIA-PACIFIC ONCOLOGY MARKET, 2008 ($ MILLIONS)
    • FIGURE 10 ASIA-PACIFIC ONCOLOGY MARKET, 2008 ($ MILLIONS)
  • GLOBAL CANCER BIOLOGICAL THERAPEUTIC MARKET
  • TABLE 26 GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2019 ($ MILLIONS)
  • FIGURE 11 GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2008-2019 ($ MILLIONS)
  • TABLE 27 U.S. BIOLOGIC DRUG SALES, 2011 AND 2012 ($ BILLIONS)
    • CANCER BIOTHERAPEUTIC MARKET SIZE AND GROWTH
    • TABLE 28 GLOBAL BIOLOGICAL MONOCLONAL, ANTIBODY CANCER TREATMENT MARKET, THROUGH 2019 ($ MILLIONS)
    • FIGURE 12 GLOBAL BIOLOGICAL MONOCLONAL ANTIBODY MARKET, 2009-2019 ($ MILLIONS)
    • TABLE 29 CANCER MONOCLONAL ANTIBODY THERAPIES
  • NEW DEVELOPMENTS
    • ARZERRA
    • NIVOLUMAB
    • TABLE 30 GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, THROUGH 2019 ($ MILLIONS)
    • FIGURE 13 GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, 2013-2019 ($ MILLIONS)
    • BEXXAR
    • ZEVALIN
    • SANOFI/GENZYME WITHDRAWS CAMPATH
    • PROMETHEUS ACQUIRES EXCLUSIVE RIGHTS TO PROLEUKIN IN THE U.S.
    • TABLE 31 SELECTED INTERFERON DRUG SALES, 2009 ($ MILLIONS)
    • ROCHE
    • TABLE 32 PATENT EXPIRIES
      • Gazyva
    • JOHNSON AND JOHNSON
    • TABLE 33 REMICADE SALES, 2012-2014 ($ MILLIONS)
      • Procrit
      • TABLE 34 PROCRIT SALES, 2009 AND 2012 ($ MILLIONS)
    • MERCK AND BRISTOL-MYERS SQUIBB
  • CANCER VACCINES
  • TABLE 35 GLOBAL BIOLOGICAL CANCER VACCINE MARKET, THROUGH 2019 ($ MILLIONS)
  • FIGURE 14 GLOBAL BIOLOGICAL CANCER VACCINE MARKET, 2009-2019 ($ MILLIONS)
  • TABLE 36 GARDASIL SALES, 2012 AND 2013 ($ MILLIONS)
    • PFIZER
    • TABLE 37 MYLOTARG SALES, 2009 ($ MILLIONS)
    • TABLE 38 GLOBAL IMMUNOSTIMULANT MARKET, THROUGH 2019 ($ MILLIONS)
    • FIGURE 15 GLOBAL IMMUNOSTIMULANT MARKET, 2009-2019 ($ MILLIONS)
    • TABLE 39 AMGEN SALES, 2012-2013 ($ MILLIONS)
    • ISSUES AND TRENDS AFFECTING THE MARKET

CHAPTER 7 PRODUCTS IN DEVELOPMENT

  • RECENT DEVELOPMENTS AND APPROVALS
  • TABLE 40 APPROVED BIOLOGICS CANCER DRUGS, 2013-2014
    • 2013 APPROVALS
  • NEW DRUGS AND COMPANIES IN DEVELOPMENT
    • ROCHE'S GAZYVA
    • AMGEN'S PROLIA
    • PFIZER'S TANEZUMAB
    • PEREGRINE'S COTARA
    • DENDREON'S PROVENGE
    • TABLE 41 PROVENGE'S KEY FEATURES
    • CEL-SCI'S MULTIKINE
    • NORTHWEST BIOTHERAPEUTICS
    • GERON
    • TABLE 42 GERON-SPONSORED CLINICAL TRIALS
    • ADVAXIS
    • TABLE 43 ADVAXIS DRUG CANDIDATES
    • AGENUS
    • ONCOTHYREON
    • IMMUNOCELLULAR THERAPEUTICS
    • INOVIO BIOMEDICAL
    • BIOVEST
    • OMNIMMUNE
    • CELLDEX THERAPEUTICS
      • CDX-1127
    • ONCOLYTICS BIOTECH
    • TABLE 44 ONCOLYTICS BIOTECH CLINICAL TRIALS
  • CLINICAL TRIALS
    • VICAL
    • PIPELINE DRUGS IN DEVELOPMENT
    • ABT-199/GDC-0199
    • TABLE 45 ABBVIE ONCOLOGY PIPELINE
    • ELOTUZUMAB
    • ABT-414
    • ABT-700
    • XBIOTECH
    • TABLE 46 ENROLLING OR COMPLETED CLINICAL STUDIES*
    • PFIZER ONCOLOGY
    • TABLE 47 PFIZER ONCOLOGY PIPELINE
  • CLINICAL TRIALS IN ONCOLOGY
  • TABLE 48 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER)
  • FIGURE 16 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER)
  • TABLE 49 APPROVED BIOLOGICS FOR CANCER, 2009
  • CONCLUSIONS

CHAPTER 8 ONCOLOGY DRUG MARKET

  • MARKET SIZE AND GROWTH
    • MARKET BY PRODUCT TYPE
      • Roche
        • Kadcyla (ado-trastuzumab emtansine)
        • Perjeta
        • Rituxan
        • TABLE 50 RITUXAN TREATMENT INDICATIONS
        • Avastin
        • Herceptin
        • Neulasta
      • Amgen
        • Xgeva
        • TABLE 51 DENOSUMAB MARKET, THROUGH 2019 ($ MILLIONS)
        • Aranesp
  • ONCOLOGY MARKET AND GROWTH
  • TABLE 52 TOP CANCER BIOLOGICS, 2007-2009 ($ MILLIONS)
  • FIGURE 17 TOP CANCER BIOLOGICS, 2007-2009 ($ MILLIONS)
    • MARKET BY REGION
    • TABLE 53 ONCOLOGY TREATMENT BY REGION, 2013
      • Oncology Pipeline
      • U.S. Cancer Market
      • TABLE 54 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
      • FIGURE 18 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
      • TABLE 55 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2007-2009
      • TABLE 56 CAMPATH SALES, 2007 AND 2008 ($ MILLIONS)
      • Japanese Cancer Market
      • TABLE 57 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
      • FIGURE 19 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
      • TABLE 58 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
      • FIGURE 20 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
      • European Cancer Market
      • TABLE 59 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
      • FIGURE 21 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
      • TABLE 60 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
      • Asia-Pacific Cancer Market
      • Australian Cancer Market
      • South Korean Cancer Market
      • Chinese Cancer Market
      • Indian Cancer Market
      • Singapore Cancer Market
      • Taiwanese Cancer Market
  • BIOMAB-EGFR
  • TABLE 61 ASIA-PACIFIC ONCOLOGY COMPANIES
  • MARKET DATA BY TOP-SELLING BIOLOGIC DRUGS
  • TABLE 62 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • FIGURE 22 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • TABLE 63 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • FIGURE 23 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)

CHAPTER 9 GLOBAL CANCER STATISTICS

  • GLOBAL CANCER INCIDENCE
  • CANCER TRENDS
  • TABLE 64 CANCER ESTIMATES, 2012 (MILLIONS)
  • TABLE 65 NEW CANCER CASES DIAGNOSED, 2012* (NUMBER/%)
  • TABLE 66 GLOBAL COMMONLY DIAGNOSED CANCERS, 2012 (MILLIONS/%)
  • TABLE 67 AGE-STANDARDIZED CANCER RATES, 2012 (PER 100,000)
    • TRENDS OVER TIME
    • GLOBAL CANCER INCIDENCE, 2008
    • TABLE 68 GLOBAL CANCER INCIDENCE BY TYPE, 2008 (MILLIONS)
    • TABLE 69 GLOBAL CANCER DEATHS BY TYPE, 2008 (MILLIONS)
    • TABLE 70 GLOBAL CANCER DISTRIBUTION BY TYPE, 2009 (MILLIONS)
    • TABLE 71 GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2009 (MILLIONS)
    • FUTURE TRENDS, 2020
    • TABLE 72 NEW CANCER CASES BY TYPE, 2020 (MILLIONS)
    • TABLE 73 GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2020 (MILLIONS)
    • CANCER CURE AND COSTS
    • RISE IN CANCER: CAUSES
    • TABLE 74 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
    • PROJECTIONS TO 2030
    • TABLE 75 GLOBAL CANCER INCIDENCE, 2008-2030 ($ MILLIONS)
    • FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030 (MILLIONS)
    • TABLE 76 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009 MILLIONS/%)
    • FIGURE 25 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009 (%)
  • CURRENT CANCER TRENDS AND ECONOMIC BURDEN
  • TABLE 77 GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008 (MILLIONS)
  • FIGURE 26 GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008 (MILLIONS)
  • TABLE 78 GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012
  • FIGURE 27 GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012 (MILLIONS)
  • TABLE 79 GLOBAL MORTALITY BY CANCER TYPE, 2012 (MILLIONS)
    • CANCER PREVALENCE AND MARKET
    • EMERGING MARKETS
      • Africa
      • Asia
      • China
      • Malaysia
      • India
      • Europe
      • Americas
      • TABLE 80 AMERICAS: CANCER FACTS
        • North America
        • TABLE 81 U.S. LEADING NEW CANCER CASES, 2014 (NUMBER/%)
        • TABLE 82 U.S. LEADING NEW CANCER CASES, 2014 (NUMBER/%)
        • TABLE 83 U.S. CANCER INCIDENCE BY TYPE, 2007-2009
        • FIGURE 28 U.S. CANCER INCIDENCE BY TYPE, 2007-2009 (MILLIONS)
        • TABLE 84 U.S. CANCER DEATHS BY TYPE, 2007-2009 (MILLIONS)
        • FIGURE 29 U.S. CANCER DEATHS BY CANCER TYPE, 2007-2009 (MILLIONS)
        • Canada

CHAPTER 10 BIOLOGIC CANCER MARKET ISSUES AND TRENDS

  • MEDICARE AND HEALTHCARE POLICIES
  • CANCER COSTS
    • CANCER DRUG COSTS
    • PERSONALIZED MEDICINE
    • PRICING STRATEGIES FOR CANCER BIOLOGICS
    • PERSONALIZED MEDICINE: USING PHARMACOGENOMICS
    • PHARMACOGENOMICS
    • TARGETED CANCER THERAPY
    • LIFESTYLES AND CANCER PREVENTION
    • MARKETING AND DISTRIBUTION TRENDS
  • GLOBAL TRENDS
  • BIOSIMILARS
    • PATENT EXPIRIES AND BIOSIMILARS
    • TABLE 85 MAJOR BIOPHARMACEUTICAL PATENT DATES ($ MILLIONS)
    • BIOSIMILARS AND COSTS OF CANCER DRUGS
    • BIOGENERICS, BIOSIMILARS AND FOLLOW-ON BIOLOGICS
    • BIOSIMILAR MANUFACTURERS
    • BIOSIMILARS IN INDIA AND CHINA
    • HURDLES FOR BIOSIMILARS
    • DATA EXCLUSIVITY PERIODS
    • DIFFERENCES BETWEEN BIOPHARMACEUTICALS AND BIOGENERICS
    • BIOSIMILARS IN EUROPE
    • ISSUES WITH BIOSIMILARS
    • ERYTHROPOIESIS-STIMULATING AGENTS OR ERYTHROPOIETINS (ESAS)
    • BIOSIMILARS
    • BIOSIMILARS AND PATIENT SAFETY
    • CURRENT BIOSIMILARS
    • SUMMARY
    • CONCLUSIONS
  • VENTURE CAPITAL AND RESEARCH INVESTMENT
    • FUNDING CANCER RESEARCH
    • TABLE 86 GLOBAL CANCER RESEARCH INVESTMENT, 2009 (MILLIONS/%)
  • CONCLUSION

CHAPTER 11 COMPANY PROFILES

  • BIOLOGIC COMPANIES
  • TABLE 87 GLOBAL BIOLOGIC DRUG PRESCRIPTION SALES, THROUGH 2014 ($ MILLIONS)
  • SELECTED COMPANIES AND PROFILES
    • ABBVIE INC.
    • AMGEN INC.
    • ASTELLAS PHARMA U.S. LLC
    • BIOGEN IDEC
    • BIOSERVICES
    • BRISTOL MYERS SQUIBB
    • CELLDEX THERAPEUTICS
    • CEL-SCI CORP.
    • DENDREON
    • ELI LILLY AND COMPANY
    • GENENTECH INC.
    • HOFFMANN-LA ROCHE INC.
    • GENMAB A/S
    • GENZYME CORP.
    • GERON CORP.
    • GLAXOSMITHKLINE
    • IMMUNOGEN
    • INOVIO
    • JOHNSON AND JOHNSON
    • MERCK & COMPANY
    • NORTHWEST BIOTHERAPEUTICS
    • NOVARTIS
    • NOVARX CORP.
    • PFIZER
    • ROCHE/GENENTECH
    • VICAL INCORPORATED

CHAPTER 12 REFERENCES

LIST OF TABLES

  • SUMMARY TABLE GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 MAIN CANCER CATEGORIES
  • TABLE 2 APPROVED RENAL CELL CANCER DRUGS
  • TABLE 3 MONOCLONAL ANTIBODIES FOR NON-HODGKIN'S LYMPHOMA TREATMENT
  • TABLE 4 BRAIN TUMOR SPECIFIC STATISTICS
  • TABLE 5 ASTROCYTOMAS
  • TABLE 6 STOMACH CANCER TYPES
  • TABLE 7 ADENOCARCINOMA STOMACH CANCER STAGES
  • TABLE 8 HEAD AND NECK CANCER TYPES
  • TABLE 9 GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 10 MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
  • TABLE 11 ANTIBODY-BASED DEVELOPMENTS WITH EPITHELIAL CELL-ADHESION MOLECULE
  • TABLE 12 GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014 ($ MILLIONS)
  • TABLE 13 U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009 ($ MILLIONS)
  • TABLE 14 ERBITUX APPROVALS
  • TABLE 15 GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014 ($ MILLIONS)
  • TABLE 16 GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014 ($ MILLIONS)
  • TABLE 17 GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014 ($ MILLIONS)
  • TABLE 18 GLOBAL BIOLOGICS SALES, 2013 ($ MILLIONS)
  • TABLE 19 GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • TABLE 20 GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • TABLE 21 APPROVED ONCOLOGY DRUGS, 2013-2014
  • TABLE 22 GLOBAL ONCOLOGY MARKET BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 23 GLOBAL ONCOLOGY SALES, 2012 AND 2013 ($ MILLIONS/%)
  • TABLE 24 ASIA-PACIFIC SOLID TUMOR MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 25 ASIA-PACIFIC ONCOLOGY MARKET, 2008 ($ MILLIONS)
  • TABLE 26 GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 U.S. BIOLOGIC DRUG SALES, 2011 AND 2012 ($ BILLIONS)
  • TABLE 28 GLOBAL BIOLOGICAL MONOCLONAL, ANTIBODY CANCER TREATMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 CANCER MONOCLONAL ANTIBODY THERAPIES
  • TABLE 30 GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 SELECTED INTERFERON DRUG SALES, 2009 ($ MILLIONS)
  • TABLE 32 PATENT EXPIRIES
  • TABLE 33 REMICADE SALES, 2012-2014 ($ MILLIONS)
  • TABLE 34 PROCRIT SALES, 2009 AND 2012 ($ MILLIONS)
  • TABLE 35 GLOBAL BIOLOGICAL CANCER VACCINE MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 36 GARDASIL SALES, 2012 AND 2013 ($ MILLIONS)
  • TABLE 37 MYLOTARG SALES, 2009 ($ MILLIONS)
  • TABLE 38 GLOBAL IMMUNOSTIMULANT MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 39 AMGEN SALES, 2012-2013 ($ MILLIONS)
  • TABLE 40 APPROVED BIOLOGICS CANCER DRUGS, 2013-2014
  • TABLE 41 PROVENGE'S KEY FEATURES
  • TABLE 42 GERON-SPONSORED CLINICAL TRIALS
  • TABLE 43 ADVAXIS DRUG CANDIDATES
  • TABLE 44 ONCOLYTICS BIOTECH CLINICAL TRIALS
  • TABLE 45 ABBVIE ONCOLOGY PIPELINE
  • TABLE 46 ENROLLING OR COMPLETED CLINICAL STUDIES*
  • TABLE 47 PFIZER ONCOLOGY PIPELINE
  • TABLE 48 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER)
  • TABLE 49 APPROVED BIOLOGICS FOR CANCER, 2009
  • TABLE 50 RITUXAN TREATMENT INDICATIONS
  • TABLE 51 DENOSUMAB MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 52 TOP CANCER BIOLOGICS, 2007-2009 ($ MILLIONS)
  • TABLE 53 ONCOLOGY TREATMENT BY REGION, 2013
  • TABLE 54 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 55 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2007-2009
  • TABLE 56 CAMPATH SALES, 2007 AND 2008 ($ MILLIONS)
  • TABLE 57 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 58 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • TABLE 59 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019 ($ MILLIONS)
  • TABLE 60 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • TABLE 61 ASIA-PACIFIC ONCOLOGY COMPANIES
  • TABLE 62 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • TABLE 63 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • TABLE 64 CANCER ESTIMATES, 2012 (MILLIONS)
  • TABLE 65 NEW CANCER CASES DIAGNOSED, 2012* (NUMBER/%)
  • TABLE 66 GLOBAL COMMONLY DIAGNOSED CANCERS, 2012 (MILLIONS/%)
  • TABLE 67 AGE-STANDARDIZED CANCER RATES, 2012 (PER 100,000)
  • TABLE 68 GLOBAL CANCER INCIDENCE BY TYPE, 2008 (MILLIONS)
  • TABLE 69 GLOBAL CANCER DEATHS BY TYPE, 2008 (MILLIONS)
  • TABLE 70 GLOBAL CANCER DISTRIBUTION BY TYPE, 2009 (MILLIONS)
  • TABLE 71 GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2009 (MILLIONS)
  • TABLE 72 NEW CANCER CASES BY TYPE, 2020 (MILLIONS)
  • TABLE 73 GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2020 (MILLIONS)
  • TABLE 74 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
  • TABLE 75 GLOBAL CANCER INCIDENCE, 2008-2030 ($ MILLIONS)
  • TABLE 76 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009 MILLIONS/%)
  • TABLE 77 GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008 (MILLIONS)
  • TABLE 78 GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012
  • TABLE 79 GLOBAL MORTALITY BY CANCER TYPE, 2012 (MILLIONS) 68
  • TABLE 80 AMERICAS: CANCER FACTS
  • TABLE 81 U.S. LEADING NEW CANCER CASES, 2014 (NUMBER/%)
  • TABLE 82 U.S. LEADING NEW CANCER CASES, 2014 (NUMBER/%)
  • TABLE 83 U.S. CANCER INCIDENCE BY TYPE, 2007-2009
  • TABLE 84 U.S. CANCER DEATHS BY TYPE, 2007-2009 (MILLIONS)
  • TABLE 85 MAJOR BIOPHARMACEUTICAL PATENT DATES ($ MILLIONS)
  • TABLE 86 GLOBAL CANCER RESEARCH INVESTMENT, 2009 (MILLIONS/%)
  • TABLE 87 GLOBAL BIOLOGIC DRUG PRESCRIPTION SALES, THROUGH 2014 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019 ($ MILLIONS)
  • FIGURE 1 GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, 2008-2019 ($ MILLIONS)
  • FIGURE 2 GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014 ($ MILLIONS)
  • FIGURE 3 U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009 ($ MILLIONS)
  • FIGURE 4 GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014 ($ MILLIONS)
  • FIGURE 5 GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014 ($ MILLIONS)
  • FIGURE 6 GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014 ($ MILLIONS)
  • FIGURE 7 GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • FIGURE 8 GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030 (MILLIONS)
  • FIGURE 9 GLOBAL ONCOLOGY MARKET BY REGION, 2008-2019 ($ MILLIONS)
  • FIGURE 10 ASIA-PACIFIC ONCOLOGY MARKET, 2008 ($ MILLIONS)
  • FIGURE 11 GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2008-2019 ($ MILLIONS)
  • FIGURE 12 GLOBAL BIOLOGICAL MONOCLONAL ANTIBODY MARKET, 2009-2019 ($ MILLIONS)
  • FIGURE 13 GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, 2013-2019 ($ MILLIONS)
  • FIGURE 14 GLOBAL BIOLOGICAL CANCER VACCINE MARKET, 2009-2019 ($ MILLIONS)
  • FIGURE 15 GLOBAL IMMUNOSTIMULANT MARKET, 2009-2019 ($ MILLIONS)
  • FIGURE 16 ONCOLOGY CLINICAL TRIALS, 2009 (NUMBER)
  • FIGURE 17 TOP CANCER BIOLOGICS, 2007-2009 ($ MILLIONS)
  • FIGURE 18 U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
  • FIGURE 19 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
  • FIGURE 20 JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009 ($ MILLIONS)
  • FIGURE 21 EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019 ($ MILLIONS)
  • FIGURE 22 GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • FIGURE 23 U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009 ($ MILLIONS)
  • FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030 (MILLIONS)
  • FIGURE 25 GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009 (%)
  • FIGURE 26 GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008 (MILLIONS)
  • FIGURE 27 GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012 (MILLIONS)
  • FIGURE 28 U.S. CANCER INCIDENCE BY TYPE, 2007-2009 (MILLIONS)
  • FIGURE 29 U.S. CANCER DEATHS BY CANCER TYPE, 2007-2009 (MILLIONS)
Back to Top